(67 days)
No
The description focuses on the physical components and mechanical function of a blood reservoir for extracorporeal circulation, with no mention of AI or ML technologies.
No
The device is described as facilitating the removal of particulate matter and micro air bubbles from blood, and storing it during extra corporeal circulation, which is a supportive function during a medical procedure, not a therapeutic treatment of a disease or condition itself.
No
The device is designed to remove particulate matter and micro air bubbles from blood and store it during extracorporeal circulation, not to diagnose medical conditions.
No
The device description clearly states it is comprised of a hardshell casing, lid assembly, defoamer, and filter, which are all physical hardware components.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use describes a device used during a medical procedure (extra corporeal circulation) to process blood outside the body. It focuses on removing physical components (particulate matter and air bubbles) and storing the blood.
- Device Description: The description details a physical device with a hardshell casing, ports, a defoamer, and a filter. These are all components of a system used for blood handling and processing during surgery.
- Lack of Diagnostic Purpose: There is no mention of the device being used to analyze blood or other biological samples to provide information for diagnosis, monitoring, or screening. IVDs are designed to provide diagnostic information.
- Performance Studies: The performance studies focus on the physical and functional performance of the device in terms of filtration, defoaming, pressure, and effects on blood components, not on diagnostic accuracy or analytical performance.
In summary, the CAPIOX® Cardiotomy Reservoir is a medical device used in a surgical setting for blood management, not for in vitro diagnostic testing.
N/A
Intended Use / Indications for Use
The CAPIOX® Cardiotomy Reservoir is designed to facilitate the removal of particulate matter and micro air bubbles from blood that is aspirated from the thoracic cavity and/or the left ventricle, and store it during extra corporeal circulation. The device may be used for procedures lasting up to 6 hours.
Product codes
DTN
Device Description
The design of the CAPIOX® Cardiotomy Reservoir is comprised of a hardshell casing that serves as a blood containment system within the bypass circuit. The upper portion of the reservoir consists of a hardshell lid assembly that contains the necessary inlet ports and vent ports. The total capacity of the reservoir is 1000 mL.
The cardiotomy section of the CAPIOX® Cardiotomy Reservoir contains a defoamer and a filter to facilitate air removal and the removal of particulates from suctioned blood entering the reservoir.
The generic materials used in the CAPIOX® Cardiotomy Reservoir are polycarbonate, polypropylene, PET, polyurethane, silicone rubber, PMMA-PHEMA and Terumo's X-Coating polymer solution.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
thoracic cavity and/or the left ventricle
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The following tests were conducted to demonstrate equivalence in performance:
- Filter Defoaming Cardiotomy Section .
- Pressure Drop Cardiotomy Section .
- Filtration Efficiency Cardiotomy Section .
- Effects Upon Cellular Blood Components .
- Pressure Integrity Testing .
- Tubing Connection Strength .
- Filter Breakthrough Time .
Key results: The cardiotomy section of the CAPIOX® Cardiotomy Reservoir is exactly the same as the cardiotomy section of the predicate CAPIOX® RX05 Hardshell Reservoir. As such, there are no performance differences between the cardiotomy sections of the two devices. The removal of the venous filter does not alter the performance of the cardiotomy filter, as the two filters operate and perform independently of each other. Additionally, comparative studies between the CAPIOX® Cardiotomy Reservoir and the predicate Medtronic Minimax Reservoir further demonstrate the substantial equivalence of the proposed device to another legally marketed device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.4400 Cardiopulmonary bypass blood reservoir.
(a)
Identification. A cardiopulmonary bypass blood reservoir is a device used in conjunction with short-term extracorporeal circulation devices to hold a reserve supply of blood in the bypass circulation.(b)
Classification. Class II (special controls), except that a reservoir that contains a defoamer or filter is classified into the same class as the defoamer or filter. The device, when it is a cardiopulmonary bypass blood reservoir that does not contain defoamers or blood filters, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
0
CAPIOX® Cardiotomy Reservoir
Submitter Information:
This premarket notification is submitted by:
Garry A. Courtney, MBA, RAC Sr. Regulatory Affairs Specialist Terumo Cardiovascular Systems Telephone: 1-800-283-7866, Ext. 7420
Date of Preparation: November 3, 2003
Device Names:
| Proprietary Name: | CAPIOX® Cardiotomy Reservoir |
|---|---|
| Common Name: | Blood Reservoir |
| Classification: | CPB Reservoirs are classified as Class II devices. |
Predicate Device:
The CAPIOX® Cardiotomy Reservoir is substantially equivalent in intended use, materials, design, technology and principles of operation, and performance to the following devices:
- CAPIOX® RX05 Hardshell Reservoir (Cardiotomy Section) K022115. t
- Medtronic Minimax Hardshell Reservoir (Cardiotomy Section) K933586. .
Intended Use:
The CAPIOX® Cardiotomy Reservoir is designed to facilitate the removal of particulate matter and micro air bubbles from blood that is aspirated from the thoracic cavity and/or the left ventricle, and store it during extra corporeal circulation. The device may be used for procedures lasting up to 6 hours.
Principles of Operation/Technology:
The CAPIOX® Cardiotomy Reservoir is used as a blood storage device during and after cardiopulmonary bypass procedures. The patient's blood enters the reservoir from the thoracic cavity and/or the left ventricle. Typically, the blood is pulled into the reservoir via suction.
The blood that is drawn from the patient enters the device via the blood inlet ports and suction ports that are positioned above the cardiotomy filter that is contained within the reservoir. The blood passes through a defoamer (to facilitate the removal of air from the blood) and through a filter for mechanical entrapment/removal of particulate matter from the blood.
1
Blood exits the device via gravity through the blood outlet port and is subsequently pumped through the remainder of the cardiopulmonary bypass circuit.
Design and Materials:
The design of the CAPIOX® Cardiotomy Reservoir is comprised of a hardshell casing that serves as a blood containment system within the bypass circuit. The upper portion of the reservoir consists of a hardshell lid assembly that contains the necessary inlet ports and vent ports. The total capacity of the reservoir is 1000 mL.
The cardiotomy section of the CAPIOX® Cardiotomy Reservoir contains a defoamer and a filter to facilitate air removal and the removal of particulates from suctioned blood entering the reservoir.
The generic materials used in the CAPIOX® Cardiotomy Reservoir are polycarbonate, polypropylene, PET, polyurethane, silicone rubber, PMMA-PHEMA and Terumo's X-Coating polymer solution.
Performance Evaluations:
The performance of the CAPIOX® Cardiotomy Reservoir is substantially equivalent to the performance of the cardiotomy sections of the aforementioned predicate devices. The following tests were conducted to demonstrate equivalence in performance:
- Filter Defoaming Cardiotomy Section .
- Pressure Drop Cardiotomy Section .
- Filtration Efficiency Cardiotomy Section .
- Effects Upon Cellular Blood Components .
- Pressure Integrity Testing .
- Tubing Connection Strength .
- Filter Breakthrough Time .
Substantial Equivalence Comparison:
The CAPIOX® Cardiotomy Reservoir is substantially equivalent to cardiotomy section of the predicate devices as indicated below:
Intended Use: The CAPIOX® Cardiotomy Reservoir and the predicate CAPIOX® RX05 Hardshell Reservoir share the same intended uses. The cardiotomy section of each device is used to facilitate the removal of particulate matter and micro air bubbles from blood that is aspirated from the thoracic cavity and/or the left ventricle, and store it during extra corporeal circulation. Each device may be used for procedures lasting up to 6 hours. The respective cardiotomy sections of these two devices are identical. Their intended uses are identical.
2
Principles of Operation/Technology: The CAPIOX® Cardiotomy Reservoir and the predicate CAPIOX® RX05 Hardshell Reservoir utilize the exact same technology in their respective operations. With each device, the patient's blood enters the reservoir from the thoracic cavity and/or the left ventricle. Typically, the blood is pulled into the reservoir via suction.
The blood that is drawn from the patient enters the devices via the blood inlet ports and suction ports that are positioned above the cardiotomy filter that is contained within the reservoirs. The blood passes through a defoamer (to remove air from the blood) and through a filter (for mechanical entrapment/removal) of particulate matter from the blood.
Blood exits the devices via gravity through the blood outlet port and is subsequently pumped through the remainder of the cardiopulmonary bypass circuit.
The principals of operation and employed technology of the two devices are identical.
Design and Materials: The design of the CAPIOX® Cardiotomy Reservoir is identical to the predicate CAPIOX® RX05 Hardshell Reservoir except that it does not contain a venous filter. As such, the materials are also identical for the two devices, excepting that a venous filter is not present in the CAPIOX® Cardiotomy Reservoir. There are no new and/or additional materials utilized in the CAPIOX® Cardiotomy Reservoir that are not also utilized in the predicate CAPIOX® RX05 Hardshell Reservoir.
Performance: The cardiotomy section of the CAPIOX® Cardiotomy Reservoir is exactly the same as the cardiotomy section of the predicate CAPIOX® RX05 Hardshell Reservoir. As such, there are no performance differences between the cardiotomy sections of the two devices. The removal of the venous filter does not alter the performance of the cardiotomy filter, as the two filters operate and perform independently of each other. Additionally, comparative studies between the CAPIOX® Cardiotomy Reservoir and the predicate Medtronic Minimax Reservoir further demonstrate the substantial equivalence of the proposed device to another legally marketed device.
Substantial Equivalence Summary:
. *
In summary, the CAPIOX® Cardiotomy Reservoir and the predicate CAPIOX® RX05 Hardshell Reservoir are substantially equivalent in intended use, principles of operation/technology, design and materials, and performance. Any noted differences between the devices do not raise new issues of safety and effectiveness. Additionally, equivalence is also demonstrated between the CAPIOX® Cardiotomy Reservoir and the Medtronic device (with respect to select performance evaluations).
Additional Safety Information:
- Sterilization conditions have been validated in accordance with AAMI guidelines to . provide a Sterility Assurance Level (SAL) of 10-6.
3
- Biocompatibility studies were conducted on the CAPIOX® RX25 Hardshcll . Reservoir - which is constructed of the same materials as the CAPIOX® Cardiotomy Reservoir. As such. Terumo makes reference to the RX25 biocompatibilty studies to support the requirements for this submission.
The biocompatibility studies were conducted on the CAPIOX® RX25 Hardshell Reservoir as recommended in the FDA General Program Memorandum #G95-1 (5/1/95): Use of International Standard ISO 10993, "Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing." |External Communicating Devices, Circulating Blood, Limited Exposure (≤ 24 hours) Contact Duration]. The blood contacting materials were found to satisfy all biocompatibility test specifications.
Conclusion:
In summary, the CAPIOX® Cardiotomy Reservoir is substantially equivalent in intended use, principles of operation/technology, design and materials, and performance to the cardiotomy section of the predicate CAPIOX® RX05 Hardshell Reservoir (K022115) and to the Medtronic Minimax Reservoir (Cardiotomy Section) - K933586.
4
Public Health Service
Image /page/4/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular in shape and contains the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the logo is a stylized symbol that resembles a human figure.
FEB 1 0 2004
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Terumo Cardiovascular Systems Corporation c/o Garry A. Courtney MBA, RAC Sr. Regulatory Affairs Specialist 125 Blue Ball Road Elkton, MD 21921
Re: K033800 CAPIOX® Cardiotomy Reservoir Regulation Number: 21 CFR 870.4400 Regulation Name: Cardiotomy Reservoir Regulatory Class: Class II (two) Product Code: DTN Dated: December 3, 2003 Received: December 5, 2003
Dear Mr. Courtney:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the cnactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
5
Page 2 -- Garry A. Courtney MBA, RAC
Please be advised that FDA's issuance of a substantial equivalence determination does not mean Please be advised that FDA's issuance of a substances with other requirements of the Act
that FDA has made a determination that your device with other requirements of the Act that FDA has made a determination in a your correct complex Federal agencies. You must
or any Federal statutes and regulations administered by registration and listin or any Federal statutes and regulations and limited to: registration and listing (21)
comply with all the Act's requirements, including, but not limited to set comply with all the Act's requirements, including, bactice requirements as set
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set CFR Part 807); labeling (21 CFR Patl on ); good manatesan; gro-if applicable, the electronic
forth in the quality systems (QS) regulation (21 CFR Pat 820); and if applicable, forth in the quality systems (QS) regulation (2 r CF (2 of the Act); 21 CFR 1000-1050.
product radiation control provisions (Sections 53 (542 of the Action Section S product radiation control provisions (Scetions 3-1-2 42 - 2-2 - 2-2 - 2-1)
This letter will allow you to begin marketing your device of your device to a legal This letter will allow you to begin marketing your advice of your device of your device to a legally
premarket notification. The FDA finding of substantial equivalence of yo premarket notification. The FDA finding of substantial equice and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
r the If you desire specific advice for your device at (301) 594-4646. Additionally, for questions on the contact the Utfice of Compilance at (501) 591-1010 act the Office of Compliance at
promotion and advertising of your device, please contine and advanced promotion and advertising of your devices, areas and the design one of information (301) 594-4639. Also, please note the regulation on and obtain. Other general information on your
premarket notification" (21CFR Part 807.97) you may obtain of Small Manufac premarket notification" (21CFN Patt 607.77 July 10 Since of Small Manufacturers,
responsibilities under the Act may be obtained from the Division of Small of (301) 44 responsibilities under the Act may be ood its toll-free number (800) 638-2041 or (301) 443-6597
International and Consumer Assistance at its toll-free mumber (800) 638-2041 o International and Consumer Tissis.com/cdrh/dsma/dsmamain.html
Sincerely yours,
uma R. Kirchner
] Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
510(k) Number (if known): K033800
CAPIOX® Cardiotomy Reservoir Device Name:
Indications For Use:
The CAPIOX® Cardiotomy Reservoir is designed to facilitate the removal of particulate matter and micro air bubbles from blood that is aspirated from the thoracic cavity and/or the left ventricle, and store it during extra corporeal circulation. The device may be used for procedures lasting up to 6 hours.
Garry A. Courtney, MBA, RAC
Terumo Cardiovascular Systems
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Concurrence of CDRH, Office of Device Evaluation (ODE)
..............................................................................................................................................................................
OR
Prescription Use X
Over-The-Counter Use
(Per 21 CFR 801.109)
Duna R. V. Jones
(Division Sign-Off) Division of Cardiovascular Devices
510(k) Number_K 033800